Occam Places Chau Cheng as VP of Investor Relations & Corporate Communications at Cytomx
CytomX is a public, clinical-stage, oncology-focused biopharmaceutical company developing antibody drug conjugates. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible.
In early 2021, Occam recruited Chau Cheng, PhD as VP, Investor Relations & Corporate Communications. Previously, Chau led investor relations at Immunomedics, Inc. for over 15 years until the company’s acquisition by Gilead Sciences for $21B.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.